|
|
FDA Approves Monthly Monitoring for Clozapine Patients - FazaClo Registry Set to Go
(Rockville, MD, April, 2005) FDA has now authorized monthly monitoring
for clozapine patients with treatment-resistant schizophrenia
who’ve experienced at least 12 months of innocuous blood test results—
and the state-of-the-art FazaClo Patient Registry is already
programmed to accept this new monitoring regimen.
FDA also has mandated that |
|
Absolute
Neutrophil Counts (ANC) be reported for
all clozapine patients and—again—the
FazaClo Patient Registry is already programmed
to accept and array this important
data for you.